Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free GTBP Stock Alerts

GT Biopharma (GTBP) Financials

GT Biopharma logo
$0.36 -0.03 (-7.43%)
As of 02:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for GT Biopharma

Annual Income Statements for GT Biopharma

This table shows GT Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -43 20 -144 -518 6.54 -28 -58 -21 -7.60 -13 -34
Consolidated Net Income / (Loss)		 -43 20 -144 -518 -39 -28 -58 -21 -7.60 -13 -28
Net Income / (Loss) Continuing Operations		 -43 20 -144 -518 6.54 -28 -58 -21 -7.60 -13 -28
Total Pre-Tax Income 		-43 20 -144 -518 6.54 -28 -58 -21 -7.60 -13 -28
Total Operating Income		 -8.93 -9.37 -136 -250 16 -6.76 -58 -21 -14 -14 -12
Total Gross Profit		 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 0.03 0.00 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 8.95 9.37 136 250 16 6.76 58 21 14 14 12
Selling, General & Admin Expense		 7.95 8.40 135 12 -9.79 6.28 48 12 7.11 8.57 8.95
Research & Development Expense		 1.00 0.98 1.07 9.07 -1.67 0.49 9.59 8.81 6.47 5.80 3.47
Total Other Income / (Expense), net		 -34 29 -8.60 -268 23 -22 -0.50 0.37 5.98 1.20 -16
Interest Expense		 17 6.56 8.60 9.12 -2.13 3.32 0.72 0.01 -0.33 0.00 0.13
Interest & Investment Income		 - - - - - - 0.04 0.29 0.78 0.40 0.12
Other Income / (Expense), net		 -17 35 - -259 20 -18 0.18 0.09 4.87 0.80 -16
Preferred Stock Dividends Declared		 - - - - - - - - - 0.00 6.10
Basic Earnings per Share		 ($8.96) $119.91 ($8.60) ($5.16) ($0.01) ($6.45) ($2.06) ($19.66) ($5.64) ($6.94) ($6.68)
Weighted Average Basic Shares Outstanding		 2.39M 81.46K 16.77M 51.37M 70.60M 4.39M 28.16M 1.06M 1.35M 1.90M 5.51M
Diluted Earnings per Share		 ($8.96) $119.91 ($8.60) ($5.16) ($0.01) ($6.45) - ($19.66) ($5.64) ($6.94) ($6.68)
Weighted Average Diluted Shares Outstanding		 2.39M 81.46K 16.77M 50.24M 3.38M 4.39M 28.16M 1.06M 1.35M 1.90M 5.51M
Weighted Average Basic & Diluted Shares Outstanding		 2.39M 122.91M 50.12M 51.37M 70.60M 4.39M 28.16M 36.81M 1.38M 2.23M 31.55M

Quarterly Income Statements for GT Biopharma

This table shows GT Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.42 -2.96 -2.27 -3.71 -3.41 -3.78 -0.78 -30 4.10 -29 -3.37
Consolidated Net Income / (Loss)		 -2.42 -2.96 -2.27 -3.71 -3.41 -3.78 -0.78 -30 8.30 -23 -2.83
Net Income / (Loss) Continuing Operations		 -2.42 -2.96 -2.27 -3.71 -3.41 -3.78 -0.78 -30 8.30 -23 -2.83
Total Pre-Tax Income 		-2.42 -2.96 -2.27 -3.71 -3.41 -3.78 -0.78 -30 8.30 -23 -2.83
Total Operating Income		 -3.12 -3.17 -3.09 -3.91 -3.60 -3.76 -1.93 -1.51 -3.38 -5.60 -2.85
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 - - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 3.12 3.17 3.09 3.91 3.60 3.76 1.93 1.51 3.38 5.60 2.85
Selling, General & Admin Expense		 1.76 1.81 2.31 2.12 2.30 1.83 0.83 1.15 2.75 4.22 2.44
Research & Development Expense		 1.36 1.36 0.78 1.78 1.31 1.93 1.10 0.36 0.63 1.38 0.41
Total Other Income / (Expense), net		 0.71 0.21 0.83 0.20 0.19 -0.01 1.16 -29 12 -17 0.02
Interest Expense		 0.00 0.00 0.00 0.00 0.00 - -1.00 0.00 0.00 1.13 0.06
Interest & Investment Income		 0.22 0.18 0.14 0.11 0.10 0.06 0.03 0.04 0.04 0.02 0.07
Other Income / (Expense), net		 0.49 0.03 0.68 0.09 0.10 -0.07 0.13 -29 12 -16 0.01
Preferred Stock Dividends Declared		 - - - 0.00 0.00 - 0.00 0.09 4.20 - 0.54
Basic Earnings per Share		 ($1.77) ($2.20) ($1.64) ($2.17) ($1.53) ($1.99) ($0.33) ($10.92) $1.04 ($5.24) ($0.11)
Weighted Average Basic Shares Outstanding		 1.37M 1.35M 1.38M 1.71M 2.23M 1.90M 2.35M 2.77M 3.94M 5.51M 30.28M
Diluted Earnings per Share		 ($1.77) ($2.20) ($1.64) ($2.17) ($1.53) ($1.99) ($0.33) ($10.92) $1.04 ($5.24) ($0.11)
Weighted Average Diluted Shares Outstanding		 1.37M 1.35M 1.38M 1.71M 2.23M 1.90M 2.35M 2.77M 3.94M 5.51M 30.28M
Weighted Average Basic & Diluted Shares Outstanding		 41.42M 1.38M 1.42M 2.23M 2.23M 2.23M 2.59M 3.56M 10.64M 31.55M 36.06M

Annual Cash Flow Statements for GT Biopharma

This table details how cash moves in and out of GT Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.81 -0.03 0.56 -0.52 -0.03 5.27 3.67 -3.30 -4.59 2.97 2.86
Net Cash From Operating Activities		 -4.66 -1.93 -5.43 -11 -3.66 -7.26 -16 -15 -8.85 -13 -13
Net Cash From Continuing Operating Activities		 -4.66 -1.93 -5.43 -11 -3.66 -7.26 -16 -15 -8.85 -13 -13
Net Income / (Loss) Continuing Operations		 -21 9.77 -144 -259 -39 -28 -58 -21 -7.60 -13 -28
Consolidated Net Income / (Loss)		 -21 9.77 -144 -259 -39 -28 -58 -21 -7.60 -13 -28
Non-Cash Adjustments To Reconcile Net Income		 3.56 -19 130 238 30 18 34 7.65 -3.19 -0.52 28
Changes in Operating Assets and Liabilities, net		 0.91 2.81 1.42 0.11 4.08 2.40 7.94 -1.98 1.94 0.78 -12
Net Cash From Investing Activities		 -0.00 0.00 -0.00 -0.04 0.20 0.00 -23 12 -2.01 13 0.00
Net Cash From Continuing Investing Activities		 -0.00 0.00 -0.00 -0.04 0.20 0.00 -23 12 -2.01 13 0.00
Sale and/or Maturity of Investments		 - - - - - - - - -2.01 13 0.00
Net Cash From Financing Activities		 3.85 1.90 5.99 10 3.43 13 42 -0.22 6.27 2.98 16
Net Cash From Continuing Financing Activities		 3.85 1.90 5.99 10 3.43 13 42 -0.22 6.27 2.98 16
Payment of Dividends		 - - - - - - - - - 0.00 -0.23
Issuance of Preferred Equity		 - - - - - - - - - 0.00 11
Issuance of Common Equity		 - - - - - 0.00 25 0.00 6.27 2.98 0.00
Other Financing Activities, net		 - - - - - 0.00 16 -0.22 - 0.00 5.50
Cash Interest Paid		 0.00 - - - 0.00 0.00 0.00 0.00 0.21 0.00 0.00
Cash Income Taxes Paid		 0.00 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for GT Biopharma

This table details how cash moves in and out of GT Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -0.12 -1.57 0.87 7.30 -2.74 -2.47 -1.59 2.86 -2.70 4.28 2.11
Net Cash From Operating Activities		 -1.96 -2.05 -4.16 -3.54 -2.74 -2.47 -2.20 -3.01 -3.68 -4.02 -2.47
Net Cash From Continuing Operating Activities		 -1.96 -2.05 -4.16 -3.54 -2.74 -2.47 -2.20 -3.01 -3.68 -4.02 -2.47
Net Income / (Loss) Continuing Operations		 -2.42 -2.96 -2.27 -3.71 -3.41 -3.78 -0.78 -30 8.30 -23 -2.83
Consolidated Net Income / (Loss)		 -2.42 -2.96 -2.27 -3.71 -3.41 -3.78 -0.78 -30 8.30 -23 -2.83
Non-Cash Adjustments To Reconcile Net Income		 0.08 0.35 -0.55 -0.01 -0.04 0.08 -0.12 28 0.15 29 0.04
Changes in Operating Assets and Liabilities, net		 0.37 0.57 -1.34 0.18 0.71 1.23 -1.30 -0.55 -12 -9.78 0.33
Net Cash From Investing Activities		 1.85 0.48 5.03 7.86 -0.00 0.00 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 1.85 0.48 5.03 7.86 -0.00 0.00 0.00 - - - 0.00
Net Cash From Financing Activities		 - - 0.00 2.98 - - 0.62 5.88 0.98 8.31 4.58
Net Cash From Continuing Financing Activities		 - - 0.00 2.98 - - 0.62 5.88 0.98 8.31 4.58
Issuance of Preferred Equity		 - - - - - - 0.00 - 1.06 4.01 4.00
Other Financing Activities, net		 - - - - - - 0.62 - - 4.44 0.58
Cash Interest Paid		 - 0.21 0.00 - - - 0.00 - - - 0.00
Cash Income Taxes Paid		 - - 0.00 - - - 0.00 - - - 0.00

Annual Balance Sheets for GT Biopharma

This table presents GT Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.05 0.03 254 25 0.40 5.66 32 17 14 4.23 8.11
Total Current Assets		 0.05 0.02 0.58 0.09 0.27 5.66 32 17 14 4.23 8.11
Cash & Equivalents		 0.05 0.02 0.58 0.06 0.03 5.30 8.97 5.67 1.08 3.95 6.81
Restricted Cash		 - - - - - - - - 0.00 0.09 0.09
Prepaid Expenses		 0.00 0.00 0.00 0.03 0.25 0.36 0.19 0.05 0.08 0.19 0.57
Other Current Assets		 - - - - - - - - - 0.00 0.63
Plant, Property, & Equipment, net		 0.01 0.00 0.01 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 254 25 0.12 0.00 0.00 0.17 0.05 0.00 0.00
Total Liabilities & Shareholders' Equity		 0.05 0.03 254 25 0.40 5.66 32 17 14 4.23 8.11
Total Liabilities		 51 19 2.68 14 20 35 10 5.00 6.63 5.90 2.32
Total Current Liabilities		 50 19 2.68 14 20 35 10 4.94 6.63 5.90 2.32
Accounts Payable		 0.89 2.10 2.55 1.76 1.94 2.24 8.19 3.14 4.33 3.85 0.75
Accrued Expenses		 38 0.64 0.10 1.02 2.38 1.30 1.90 1.67 1.20 1.80 1.56
Other Current Liabilities		 7.99 1.17 0.03 0.03 0.15 0.38 0.14 0.11 1.11 0.25 0.01
Total Noncurrent Liabilities		 0.71 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -51 -19 252 11 -19 -29 22 12 7.48 -1.67 5.79
Total Preferred & Common Equity		 -51 -19 252 12 -19 -29 22 12 7.48 -1.67 5.79
Preferred Stock		 - - - 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -50 -19 252 12 -19 -29 22 12 7.48 -1.67 5.79
Common Stock		 84 106 521 540 548 566 674 686 690 694 730
Retained Earnings		 -134 -125 -269 -529 -567 -596 -654 -674 -682 -695 -724

Quarterly Balance Sheets for GT Biopharma

This table presents GT Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 16 9.91 9.27 6.76 2.66 7.12 4.32 10.00
Total Current Assets		 16 9.89 9.27 6.76 2.66 7.12 4.32 10.00
Cash & Equivalents		 2.65 1.95 9.25 6.42 2.37 5.23 2.53 8.92
Restricted Cash		 - - - 0.09 0.09 0.09 0.09 0.09
Prepaid Expenses		 0.04 0.08 0.02 0.25 0.20 1.04 0.94 0.41
Other Current Assets		 - - - - - 0.76 0.76 0.57
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.10 0.03 0.00 0.00 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 16 9.91 9.27 6.76 2.66 7.12 4.32 10.00
Total Liabilities		 6.14 4.60 3.76 4.66 3.64 31 1.32 2.42
Total Current Liabilities		 5.09 4.60 3.76 4.66 3.64 31 1.32 2.42
Accounts Payable		 3.97 3.21 1.72 2.61 2.38 1.37 0.77 0.25
Accrued Expenses		 1.03 0.96 1.77 1.87 1.13 0.61 0.40 2.16
Other Current Liabilities		 0.09 0.03 0.00 0.18 0.13 29 0.01 0.00
Total Noncurrent Liabilities		 1.05 0.39 0.28 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 10 5.31 5.51 2.10 -0.98 -26 3.00 7.58
Total Preferred & Common Equity		 10 5.31 5.51 2.10 -0.98 -26 3.00 7.58
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 10 5.31 5.51 2.10 -0.98 -26 3.00 7.58
Common Stock		 689 690 694 694 695 700 721 734
Retained Earnings		 -679 -684 -688 -691 -696 -726 -718 -727

Annual Metrics And Ratios for GT Biopharma

This table displays calculated financial ratios and metrics derived from GT Biopharma's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 600,000,000.00 60,482,610.00 49,767,978.00 50,227,978.00 67,432,198.00 78,268,614.00 30,582,354.00 32,557,720.00 41,418,999.00 2,234,328.00 21,272,270.00
DEI Adjusted Shares Outstanding		 1,176,471.00 118,593.00 97,584.00 98,486.00 132,220.00 153,468.00 1,019,412.00 1,085,257.00 1,380,633.00 2,234,328.00 21,272,270.00
DEI Earnings Per Adjusted Shares Outstanding		 -36.48 164.73 -1,477.41 -5,263.41 49.43 -184.38 -56.91 -19.24 -5.50 -5.89 -1.62
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -55.74% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 62.68% 326.04% -519.51% -288.51% 107.42% -166.60% -132.50% 63.08% 58.85% -55.71% -109.01%
EBIT Growth		 38.15% 200.80% -619.60% -275.64% 107.17% -168.39% -129.55% 63.08% 58.85% -55.71% -109.01%
NOPAT Growth		 -272.58% -50.01% -912.36% -84.46% 109.17% -129.49% -750.31% 63.04% 36.13% -5.80% 13.52%
Net Income Growth		 8.66% 145.52% -837.98% -259.55% 92.54% 26.78% -105.02% 64.00% 63.62% -73.25% -115.42%
EPS Growth		 -22,300.00% 1,438.28% -107.17% 40.00% 92.54% 26.78% 0.00% 0.00% 63.62% -23.05% 3.75%
Operating Cash Flow Growth		 -166.27% 58.56% -181.35% -96.63% 65.73% -98.47% -114.90% 2.49% 41.83% -45.78% -0.08%
Free Cash Flow Firm Growth		 -39.34% -499.55% -573.67% 115.30% -20.31% -112.37% -539.93% 40.37% 61.37% -39.27% -22.65%
Invested Capital Growth		 -70.71% 91.60% 6,532.20% -91.03% -118.22% 13.26% -182.12% 52.44% -36.07% 12.04% 80.43%
Revenue Q/Q Growth		 -55.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -41.09% 439.67% -5.03% -104.66% 323.99% -185.92% -90.06% 36.50% 23.83% -5.38% -2.78%
EBIT Q/Q Growth		 -21.46% 271.38% -3.88% -101.39% 299.75% -187.19% -90.06% 36.50% 23.83% -5.38% -2.78%
NOPAT Q/Q Growth		 -16.53% -16.85% -3.88% 1.11% 225.46% -116.53% -32.22% 36.84% 16.13% -4.32% -17.30%
Net Income Q/Q Growth		 -30.71% 172.27% 4.73% -90.14% 86.27% 35.61% -124.73% 37.33% 25.66% -6.58% -7.32%
EPS Q/Q Growth		 -264.23% 2,280.18% -100.00% 5.15% 86.27% 35.61% 0.00% 37.33% 25.66% -25.50% 14.25%
Operating Cash Flow Q/Q Growth		 1.98% 29.54% -59.10% 7.84% 17.18% -24.78% -12.86% -4.06% 20.27% -3.37% -13.67%
Free Cash Flow Firm Q/Q Growth		 158.03% -252.77% 1.37% 4.38% 207.43% -119.13% -14.29% 10.74% 23.35% 3.53% -7.62%
Invested Capital Q/Q Growth		 -142.76% 68.62% 0.05% -0.72% -2.55% -20.81% -161.61% 1.16% -8.10% -29.45% -313.77%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -50,174.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -33,062.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -95,862.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -158,970.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% -591.38% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 165.83% 74.88% 106.35% 101.79% 17.89% 113.29% 101.19% 98.66% 87.21% 97.04% 100.01%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 107.11% -56.22% -123.88% -394.11% 973.48% 116.10% 1,542.28% -124.15% -79.09% -453.39% -1,377.41%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -139.35% 39.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -5,495.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -9,112.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 106.89% -55.95% -124.06% -394.61% 932.65% 115.71% 1,543.10% -124.14% -79.09% -453.24% -1,376.74%
Return on Equity Simple (ROE_SIMPLE)		 84.88% -104.15% -57.24% -4,492.35% 201.94% 96.14% -264.78% -177.98% -101.62% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.25 -9.37 -95 -175 16 -4.73 -40 -15 -9.50 -10 -8.70
NOPAT Margin		 -23,144.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 1,137.50% -302.45% 682.26% 6,496.81% 415.16% 114.70% -584.64% -24.78% 12.51% -34.49% -359.09%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -127.12% 602.08% -150.26%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 29,459.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 3,703.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 33,162.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -26 26 -136 -509 37 -25 -57 -21 -8.71 -14 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -14 31 -128 -499 37 -25 -57 -21 -8.71 -14 -28
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 4.05 0.00 0.00 4.24 2.46 1.41 0.00 1.44
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 4.24 2.46 1.41 0.00 1.44
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.84 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 119.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 2.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.50 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.51 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 1.15 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 1.07 0.43 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.03 -0.59 0.00 0.95 -0.68 -0.89 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.08 -0.28 0.06 0.04 -3.32 -0.84 0.81 -1.44 -1.59 -3.10 -2.66
Leverage Ratio		 -0.01 0.00 1.09 1.06 -3.25 -0.12 -5.03 1.45 1.61 3.16 3.00
Compound Leverage Factor		 -0.02 0.00 1.16 1.08 -0.58 -0.14 -5.09 1.43 1.40 3.07 3.00
Debt to Total Capital		 -3.59% -146.25% 0.00% 48.65% -216.40% -840.35% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 -2.13% -146.25% 0.00% 48.65% -216.40% -840.35% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 -1.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.01% -0.10% -0.10% 0.00% 0.01% 0.01% -0.06% 0.02%
Noncontrolling Interests to Total Capital		 0.00% 2.20% -0.07% -0.76% 2.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 103.24% 244.09% 100.07% 52.10% 313.68% 940.45% 100.00% 99.99% 99.99% 100.06% 99.98%
Debt to EBITDA		 -0.13 0.37 0.00 -0.02 0.36 -1.07 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -0.13 0.37 0.00 -0.02 0.36 -0.85 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.28 -1.20 0.00 -0.06 0.82 -5.56 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -0.27 -1.20 0.00 -0.06 0.82 -4.44 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -93.97 -1,760.11 -167.96 -28.07 -56.30 -68.13 -240.35 -133.55
Noncontrolling Interest Sharing Ratio		 0.21% 0.48% -0.14% -0.13% 4.19% 0.33% -0.05% 0.01% 0.01% 0.03% 0.05%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 0.00 0.22 0.01 0.01 0.16 3.14 3.35 2.12 0.72 3.50
Quick Ratio		 0.00 0.00 0.22 0.00 0.00 0.15 3.12 3.34 2.11 0.67 2.94
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 13 -52 -350 54 43 -5.28 -34 -20 -7.78 -11 -13
Operating Cash Flow to CapEx		 -465,700.00% 0.00% -135,750.00% -29,658.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.76 -7.92 -40.68 5.87 0.00 -1.59 -47.05 -2,517.99 0.00 0.00 -104.66
Operating Cash Flow to Interest Expense		 -0.27 -0.29 -0.63 -1.17 0.00 -2.19 -21.74 -1,902.13 0.00 0.00 -101.69
Operating Cash Flow Less CapEx to Interest Expense		 -0.27 -0.29 -0.63 -1.18 0.00 -2.19 -21.74 -1,902.13 0.00 0.00 -101.69
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 4.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -46 -3.90 251 23 -4.10 -3.56 -10 -4.77 -6.50 -5.71 -1.12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -19 43 255 -229 -27 0.54 -6.48 5.26 -1.72 0.78 4.60
Enterprise Value (EV)		 0.00 0.00 0.00 57 18 32 61 12 -3.41 2.77 1.45
Market Capitalization		 0.00 0.00 0.00 47 5.46 11 93 29 11 6.81 8.35
Book Value per Share		 ($0.08) ($0.62) $5.06 $0.23 ($0.28) ($0.38) $0.72 $0.36 $0.18 ($0.75) $0.54
Tangible Book Value per Share		 ($0.08) ($0.62) ($0.04) ($0.27) ($0.28) ($0.38) $0.72 $0.36 $0.18 ($0.75) $0.54
Total Capital		 -49 -7.69 252 22 -6.10 -3.13 22 12 7.48 -1.67 5.79
Total Debt		 1.75 11 0.00 11 13 26 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 1.71 11 -0.58 11 13 21 -32 -17 -14 -4.04 -6.91
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -49 -7.71 -2.68 -3.23 -6.25 -8.43 -10 -4.88 -6.55 -5.71 -1.12
Debt-free Net Working Capital (DFNWC)		 -49 -7.69 -2.10 -3.17 -6.23 -3.13 22 12 7.42 -1.67 5.79
Net Working Capital (NWC)		 -50 -19 -2.10 -14 -19 -29 22 12 7.42 -1.67 5.79
Net Nonoperating Expense (NNE)		 37 -29 49 343 55 24 18 6.00 -1.91 3.11 20
Net Nonoperating Obligations (NNO)		 4.10 15 -0.58 11 15 26 -32 -17 -14 -4.04 -6.91
Total Depreciation and Amortization (D&A)		 12 4.53 7.11 10 0.51 0.32 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -180,992.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 -180,818.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 -184,666.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($6,971.70) $438.60 ($4,355.40) ($2,631.60) ($341.70) ($193.50) ($61.80) ($19.80) ($5.64) ($6.94) ($6.68)
Adjusted Weighted Average Basic Shares Outstanding		 42.19K 241.01K 32.88K 98.51K 138.44K 146.17K 1.07M 1.06M 1.35M 1.90M 5.51M
Adjusted Diluted Earnings per Share		 ($6,971.70) $438.60 ($4,355.40) ($2,631.60) ($341.70) ($193.50) ($61.80) $0.00 ($5.64) ($6.94) ($6.68)
Adjusted Weighted Average Diluted Shares Outstanding		 42.19K 241.01K 32.88K 98.51K 112.80K 146.17K 1.07M 1.23M 1.35M 1.90M 5.51M
Adjusted Basic & Diluted Earnings per Share		 ($6,971.70) $438.60 $0.00 $0.00 ($341.70) ($193.50) ($61.80) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.70K 47.90K 98.27K 100.73K 138.44K 146.17K 938.52K 1.23M 1.38M 2.23M 31.55M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.25 -6.56 -95 -15 8.02 -4.73 -40 -15 -9.50 -10 -8.70
Normalized NOPAT Margin		 -23,144.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -158,970.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -1.52 3.98 -15.76 -55.86 0.00 -7.52 -79.85 -2,646.00 0.00 0.00 -223.23
NOPAT to Interest Expense		 -0.37 -1.43 -11.03 -19.20 0.00 -1.43 -56.07 -1,859.99 0.00 0.00 -68.47
EBIT Less CapEx to Interest Expense		 -1.52 3.98 -15.76 -55.86 0.00 -7.52 -79.85 -2,646.00 0.00 0.00 -223.23
NOPAT Less CapEx to Interest Expense		 -0.37 -1.43 -11.03 -19.20 0.00 -1.43 -56.07 -1,859.99 0.00 0.00 -68.47
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.81%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.81%

Quarterly Metrics And Ratios for GT Biopharma

This table displays calculated financial ratios and metrics derived from GT Biopharma's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 40,639,688.00 41,418,999.00 1,380,633.00 1,416,651.00 2,234,328.00 2,234,328.00 2,234,328.00 2,586,397.00 7,115,004.00 21,272,270.00 31,553,892.00
DEI Adjusted Shares Outstanding		 1,354,656.00 1,380,633.00 1,380,633.00 1,416,651.00 2,234,328.00 2,234,328.00 2,234,328.00 2,586,397.00 7,115,004.00 21,272,270.00 31,553,892.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.78 -2.15 -1.64 -2.62 -1.53 -1.69 -0.35 -11.70 0.58 -1.36 -0.11
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 61.75% 46.46% -238.20% -71.46% -33.24% -22.02% 25.00% -691.80% 335.61% -471.80% -57.09%
EBIT Growth		 61.75% 46.46% -238.20% -71.46% -33.24% -22.02% 25.00% -691.80% 335.61% -471.80% -57.09%
NOPAT Growth		 55.55% 45.17% 15.66% -7.87% -15.44% -18.78% 37.50% 61.26% -34.06% -48.68% -47.41%
Net Income Growth		 64.89% 46.96% -898.24% -86.25% -41.18% -27.45% 65.75% -713.18% 343.30% -510.09% -265.08%
EPS Growth		 64.89% 46.96% -680.95% -45.64% 13.56% 9.55% 79.88% -403.23% 167.97% -163.32% 66.67%
Operating Cash Flow Growth		 32.69% 52.37% -43.26% -82.74% -39.36% -20.57% 47.11% 14.76% -34.34% -62.93% -12.08%
Free Cash Flow Firm Growth		 74.35% 94.68% 79.09% -12.88% -309.16% -589.29% -51.66% 568.08% -102.03% -149.19% -65.79%
Invested Capital Growth		 -24.41% -36.07% -14.67% 39.76% 26.54% 12.04% 23.52% -679.34% 111.85% 80.43% 58.20%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -18.29% -19.38% 23.36% -58.43% 8.07% -9.32% 52.90% -1,572.59% 127.35% -365.32% 87.06%
EBIT Q/Q Growth		 -18.29% -19.38% 23.36% -58.43% 8.07% -9.32% 52.90% -1,572.59% 127.35% -365.32% 87.06%
NOPAT Q/Q Growth		 13.78% -1.47% 2.43% -26.37% 7.73% -4.41% 48.66% 21.69% -219.33% -15.80% 49.10%
Net Income Q/Q Growth		 -21.29% -22.60% 23.50% -63.72% 8.06% -10.67% 79.44% -3,787.76% 127.51% -377.52% 87.70%
EPS Q/Q Growth		 -21.29% -22.60% 25.45% -32.32% 29.49% -30.07% 83.42% -3,209.09% 109.52% -603.85% 97.90%
Operating Cash Flow Q/Q Growth		 -1.50% -4.23% -103.37% 15.06% 22.60% 9.83% 10.78% -36.88% -22.00% -9.36% 38.62%
Free Cash Flow Firm Q/Q Growth		 78.17% 50.76% -220.56% -227.51% 20.86% 17.04% 29.47% 1,110.83% -134.16% -2.33% 53.07%
Invested Capital Q/Q Growth		 3.24% -8.10% 30.80% 16.77% -17.99% -29.45% 39.83% -748.02% 101.79% -313.77% -28.53%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 91.79% 94.27% 94.10% 97.25% 97.26% 98.46% 42.97% 99.87% 100.44% 105.05% 99.86%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -78.73% -79.09% -104.94% -131.48% -204.08% -453.39% -538.87% 414.22% -1,036.73% -1,377.41% -921.55%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,361.38% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -78.73% -79.09% -104.93% -131.47% -204.05% -453.24% -538.62% 458.27% -1,036.32% -1,376.74% -921.27%
Return on Equity Simple (ROE_SIMPLE)		 -102.14% 0.00% -181.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.19 -2.22 -2.16 -2.73 -2.52 -2.63 -1.35 -1.06 -3.38 -3.92 -1.99
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.25% -4.88% -0.76% -7.17% -7.89% -12.67% 9.40% -401.93% 259.92% -349.16% -14.63%
Return On Investment Capital (ROIC_SIMPLE)		 - -29.66% -40.73% -49.64% -120.31% 157.73% 138.00% 4.09% -112.73% -67.68% -26.30%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.63 -3.14 -2.41 -3.82 -3.51 -3.83 -1.81 -30 8.26 -22 -2.84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.63 -3.14 -2.41 -3.82 -3.51 -3.83 -1.81 -30 8.26 -22 -2.84
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.98 1.41 1.15 0.73 2.46 0.00 0.00 0.00 0.70 1.44 0.19
Price to Tangible Book Value (P/TBV)		 0.98 1.41 1.15 0.73 2.46 0.00 0.00 0.00 0.70 1.44 0.19
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.33 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.42 -1.59 -1.46 -1.58 -1.86 -3.10 -2.83 0.79 -1.76 -2.66 -1.74
Leverage Ratio		 1.43 1.61 1.63 1.59 1.89 3.16 2.90 -0.89 2.17 3.00 1.92
Compound Leverage Factor		 1.32 1.51 1.54 1.54 1.84 3.11 1.25 -0.89 2.18 3.15 1.91
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.01% 0.01% 0.02% 0.02% 0.05% -0.06% -0.10% 0.00% 0.03% 0.02% 0.01%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.18% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.99% 99.99% 99.98% 99.98% 99.95% 100.06% 100.10% 108.18% 99.97% 99.98% 99.99%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -57.64 -66.83 -96.02 -103.95 -143.90 -232.76 -368.49 -160.57 -224.57 -130.93 -101.46
Noncontrolling Interest Sharing Ratio		 0.01% 0.01% 0.01% 0.01% 0.02% 0.03% 0.05% -10.63% 0.04% 0.05% 0.03%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.15 2.12 2.15 2.47 1.45 0.72 0.73 0.23 3.27 3.50 4.14
Quick Ratio		 3.15 2.11 2.13 2.46 1.38 0.67 0.65 0.17 1.91 2.94 3.69
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.01 -0.50 -1.59 -5.20 -4.12 -3.42 -2.41 24 -8.32 -8.51 -3.99
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -495.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -7.57 -63.41
Operating Cash Flow to Interest Expense		 0.00 -2,047.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3.57 -39.17
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -2,047.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3.57 -39.17
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -6.01 -6.50 -4.50 -3.74 -4.41 -5.71 -3.44 -29 0.52 -1.12 -1.44
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -1.18 -1.72 -0.58 2.47 1.60 0.78 1.06 -25 4.94 4.60 2.00
Enterprise Value (EV)		 -6.21 -3.41 -3.69 -5.24 -1.35 2.77 2.35 5.90 -0.53 1.45 -7.56
Market Capitalization		 9.80 11 6.12 4.01 5.16 6.81 4.80 9.26 2.09 8.35 1.45
Book Value per Share		 $0.25 $0.18 $3.85 $3.89 $0.94 ($0.75) ($0.44) ($10.00) $0.84 $0.54 $2.13
Tangible Book Value per Share		 $0.25 $0.18 $3.85 $3.89 $0.94 ($0.75) ($0.44) ($10.00) $0.84 $0.54 $2.13
Total Capital		 10 7.48 5.31 5.51 2.10 -1.67 -0.98 -24 3.00 5.79 7.58
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -16 -14 -9.81 -9.25 -6.51 -4.04 -2.46 -5.32 -2.62 -6.91 -9.02
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.05 -6.55 -4.52 -3.74 -4.41 -5.71 -3.44 -29 0.38 -1.12 -1.44
Debt-free Net Working Capital (DFNWC)		 11 7.42 5.29 5.51 2.10 -1.67 -0.98 -24 3.00 5.79 7.58
Net Working Capital (NWC)		 11 7.42 5.29 5.51 2.10 -1.67 -0.98 -24 3.00 5.79 7.58
Net Nonoperating Expense (NNE)		 0.23 0.74 0.10 0.98 0.89 1.14 -0.58 29 -12 19 0.84
Net Nonoperating Obligations (NNO)		 -16 -14 -9.81 -9.25 -6.51 -4.04 -2.46 -5.24 -2.48 -6.91 -9.02
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.80) ($66.00) ($1.64) ($2.17) ($1.53) ($1.99) ($0.33) ($10.92) $1.04 ($5.24) ($0.11)
Adjusted Weighted Average Basic Shares Outstanding		 1.37M 44.92K 1.38M 1.71M 2.23M 1.90M 2.35M 2.77M 3.94M 5.51M 30.28M
Adjusted Diluted Earnings per Share		 ($1.80) ($66.00) ($1.64) ($2.17) ($1.53) ($1.99) ($0.33) ($10.92) $1.04 ($5.24) ($0.11)
Adjusted Weighted Average Diluted Shares Outstanding		 1.37M 44.92K 1.38M 1.71M 2.23M 1.90M 2.35M 2.77M 3.94M 5.51M 30.28M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($66.00) $0.00 $0.00 $0.00 ($1.99) $0.00 $0.00 $0.00 ($5.24) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.38M 46.02K 1.42M 2.23M 2.23M 2.23M 2.59M 3.56M 10.64M 31.55M 36.06M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.19 -2.22 -2.16 -2.73 -2.52 -2.63 -1.35 -1.06 -2.37 -3.92 -1.99
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -3,142.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -19.49 -45.03
NOPAT to Interest Expense		 0.00 -2,217.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3.48 -31.64
EBIT Less CapEx to Interest Expense		 0.00 -3,142.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -19.49 -45.03
NOPAT Less CapEx to Interest Expense		 0.00 -2,217.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3.48 -31.64
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.32% -0.81% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.32% -0.81% 0.00%

Financials Breakdown Chart

GT Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, GT Biopharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

GT Biopharma's net income appears to be on a downward trend, with a most recent value of -$28.35 million in 2025, falling from -$42.92 million in 2015. The previous period was -$13.16 million in 2024. Check out GT Biopharma's forecast to explore projected trends and price targets.

GT Biopharma's total operating income in 2025 was -$12.42 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $12.42 million

Over the last 10 years, GT Biopharma's total revenue changed from $27 thousand in 2015 to $0.00 in 2025, a change of -100.0%.

GT Biopharma's total liabilities were at $2.32 million at the end of 2025, a 60.7% decrease from 2024, and a 95.4% decrease since 2015.

In the past 10 years, GT Biopharma's cash and equivalents has ranged from $19 thousand in 2016 to $8.97 million in 2021, and is currently $6.81 million as of their latest financial filing in 2025.

Over the last 10 years, GT Biopharma's book value per share changed from -0.08 in 2015 to 0.54 in 2025, a change of -747.6%.


Related Companies

Financial statements for NASDAQ:GTBP last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel